Pharmaceuticals

Epitranscriptomic Therapies Market Performance Outlook 2026–2030: Revenue to Hit $4.2 Billion at 21.9% CAGR

March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the epitranscriptomic therapies market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Epitranscriptomic Therapies Market covering 2026–2035?

The epitranscriptomic therapies market has seen substantial growth in recent years. It is forecast to expand from $1.56 billion in 2025 to $1.9 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 21.6%. This historical development can be ascribed to advancements in RNA biology research, a deeper understanding of gene regulation mechanisms, the expansion of oncology research programs, the widespread availability of advanced sequencing technologies, and a rise in translational medicine initiatives.

The epitranscriptomic therapies market is projected to experience rapid expansion in the coming years, reaching $4.2 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 21.9%. This anticipated growth is driven by several factors, including escalating investments in rna-based therapeutics, a growing need for targeted cancer treatments, the broader adoption of personalized medicine strategies, heightened clinical trial activity within epitranscriptomics, and increased regulatory involvement concerning new rna therapies. Key trends identified for this period encompass the accelerated development of epitranscriptomic drug pipelines, the increased utilization of rna modification profiling tools, the expansion of combined epitranscriptomic therapies, the growing incorporation of bioinformatics into therapy design, and a stronger emphasis on precision medicine applications.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33108&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Epitranscriptomic Therapies Market?

The epitranscriptomic therapies market is anticipated to expand going forward, driven by the increasing demand for personalized medicine. Personalized medicine represents a medical approach that customizes healthcare decisions, treatments, and interventions to align with each patient’s unique characteristics, including their genetic profile, lifestyle, and environment. The rising prevalence of chronic and complex diseases primarily fuels this demand, as tailored treatments can more effectively address individual patient needs and improve outcomes. Personalized medicine further supports epitranscriptomic therapies by customizing treatments to an individual’s specific RNA modification patterns, thereby enhancing therapeutic effectiveness and reducing the risk of adverse effects. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, an increase from six approvals in 2022. The newly approved personalized treatments for 2023 also included seven cancer drugs and three for other diseases and conditions. Consequently, the increasing demand for personalized medicine is propelling the growth of the epitranscriptomic therapies market.

What Leading Segments Are Studied In The Epitranscriptomic Therapies Market?

The epitranscriptomic therapies market covered in this report is segmented –

1) By Therapy Type: Small Molecule Inhibitors; Ribonucleic Acid Modifying Enzymes; Antisense Oligonucleotides; Other Therapy Types

2) By Route of Administration: Injectable; Oral; Other Routes Of Administration

3) By Application: Cancer; Neurological Disorders; Metabolic Diseases; Infectious Diseases; Other Applications

4) By End-User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users

Subsegments:

1) By Small Molecule Inhibitors: Methyltransferase Inhibitors; Demethylase Inhibitors; Reader Protein Inhibitors; Writer Enzyme Inhibitors; Eraser Enzyme Inhibitors

2) By Ribonucleic Acid Modifying Enzymes: Methyltransferase Enzymes; Demethylase Enzymes; Pseudouridine Synthase Enzymes; Adenosine Deaminase Enzymes; Cytidine Deaminase Enzymes

3) By Antisense Oligonucleotides: Gapmer Oligonucleotides; Splice Modulating Oligonucleotides; Translation Blocking Oligonucleotides; Exon Skipping Oligonucleotides; Gene Expression Silencing Oligonucleotides

4) By Other Therapy Types: Ribonucleic Acid Interference Based Therapies; Messenger Ribonucleic Acid Editing Therapies; Epitranscriptomic Vaccine Platforms; Gene Regulation Modulation Therapies; Combination Epitranscriptomic Therapies

What Trends Are Expected To Impact The Competitive Landscape Of The Epitranscriptomic Therapies Market?

Leading entities within the epitranscriptomic therapies market are increasingly concentrating on forming strategic alliances to create novel RNA-modifying treatments for cancer. Such partnerships represent collaborative structures where organizations pool their resources, expertise, or capabilities to achieve common goals, thereby fostering quicker expansion, reducing operational hazards, and boosting market standing. A notable example occurred in January 2026, when STORM Therapeutics Ltd., a biotechnology firm located in the UK, collaborated with Alida Biosciences Inc., a technology company from the US, with the aim of progressing cancer treatments focused on epitranscriptomic pathways. This cooperative effort centers on incorporating AlidaBio’s EpiPlex and EpiScout platforms into STORM’s ongoing clinical trials for STC-15, which is recognized as a pioneering METTL3 inhibitor. The primary objective of this alliance is to pinpoint and authenticate m6A RNA modification biomarkers capable of foretelling patient reactions and refining therapeutic approaches. This joint venture unites drug discovery initiatives with sophisticated RNA profiling techniques, signifying a considerable advancement in the field of epitranscriptomic cancer treatments.

Which Key Market Players Are Investing In Expansion And Innovation Within The Epitranscriptomic Therapies Market?

Major companies operating in the epitranscriptomic therapies market are AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/epitranscriptomic-therapies-market-report

Which Regions Are Poised For Strategic Growth In The Epitranscriptomic Therapies Market?

North America was the largest region in the epitranscriptomic therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epitranscriptomic therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Epitranscriptomic Therapies Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33108&type=smp

Browse Through More Reports Similar to the Global Epitranscriptomic Therapies Market 2026, By The Business Research Company

Ecoa Esource And Clinical Trials Market Report 2026

https://www.thebusinessresearchcompany.com/report/ecoa-esource-and-clinical-trials-global-market-report

Epilepsy Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795